<DOC>
	<DOCNO>NCT00219726</DOCNO>
	<brief_summary>The aim phase II trial ass tolerability effectiveness imatinib patient chronic myelogenous leukemia chronic phase relapse stem cell transplantation .</brief_summary>
	<brief_title>Safety Efficacy Imatinib Chronic Myelogenous Patients Relapse After Stem Cell Transplantation</brief_title>
	<detailed_description>Patients receive Imatinib dose 400mg daily . The tolerability Imatinib give daily dose 400mg assessed . The hematologic , cytogenetic molecular response evaluate various check point . Donor/recipient chimerism Imatinib therapy assess . Survival estimate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>CML Ph+ ( assess cytogenetic FISH ) Age â‰¥ 18 year inclusion PS grade 0 2 ( ECOG ) previous allogeneic stem cell transplantation molecular , cytogenetic haematological relapse chronic phase transplantation Immune therapy graft versus host disease stop within 2 month inclusion Adequate organ function , define follow : total bilirubin &lt; 3x uln , sgpt &lt; 3x uln , creatinine &lt; 2x uln . informed consent sign Age le 18 accelerated blastic phase previous therapy imatinib active malignancy CML nonmelanoma cancer skin current treatment another investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>CML</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Stem cell transplantation</keyword>
</DOC>